SCHWARZ PHARMA ACQUIRES REMAINING RIGHTS TO ROTIGOTINE FROM ADERIS

SCHWARZ PHARMA announced today that it has acquired all remaining rights to the rotigotine compound from Aderis Pharmaceuticals, Inc., USA. This transaction results in a one-time, non-recurring, in-process R&D expense of approximately €58 million. As a result, the break-even outlook for 2005 will be impacted by the one-time expense of €58 million resulting in a net loss of approximately €58 million. However, on an adjusted basis the net income outlook remains unchanged at break-even level.

Vereinigte Wirtschaftsdienste (http://www.vwd.de/vwd/news.htm?id=23872796&navi=home&sektion=adhoc)